Skip to main content
Clinical Trials/EUCTR2014-005418-45-SE
EUCTR2014-005418-45-SE
Active, not recruiting
Phase 1

Improved cardiovascular risk factors and inflammatory markers in Rheumatoid Arthritis and Systemic Lupus Erythematosus? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE) - HCQCVDRASLE

Christine Bengtsson0 sitesMarch 18, 2015

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Sponsor
Christine Bengtsson
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 18, 2015
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Christine Bengtsson

Eligibility Criteria

Inclusion Criteria

  • Male or female, 18\-65 years of age, who has given written consent for his/her par\-ticipation to the study
  • ACR criteria for RA and SLE
  • \< 10mg Prednisolon daily doses
  • Low\-medium disease activity DAS28 \<4\.6\-RA, SLEDAI\-2k \<6 SLE (Arthritis accepted)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 44
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 4

Exclusion Criteria

  • Antimalarial medication less than5 ½\-t\= 250 days before study inclusion visit
  • High disease activity, where cortison ad\-justment is predictable
  • Pleuritis or Pericarditis – SLE
  • Impaired visus and/or colour vision
  • Hypertension \>160/95
  • Short life expectancy due to other comor\-bidity
  • Documented allergy or intolerance to study drug
  • Severe psychiatric condition or other reason that jeopardize compliance with fol\-low up.
  • On fertile females, pregnancy assessed by anamnesis and pregnancy test

Outcomes

Primary Outcomes

Not specified

Similar Trials